Regencell Operating Income vs Interest Expense Analysis

RGC Stock  USD 5.35  0.25  4.90%   
Regencell Bioscience financial indicator trend analysis is much more than just breaking down Regencell Bioscience prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Regencell Bioscience is a good investment. Please check the relationship between Regencell Bioscience Operating Income and its Interest Expense accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

Operating Income vs Interest Expense

Operating Income vs Interest Expense Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Regencell Bioscience Operating Income account and Interest Expense. At this time, the significance of the direction appears to have very week relationship.
The correlation between Regencell Bioscience's Operating Income and Interest Expense is 0.21. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Interest Expense in the same time period over historical financial statements of Regencell Bioscience Holdings, assuming nothing else is changed. The correlation between historical values of Regencell Bioscience's Operating Income and Interest Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Regencell Bioscience Holdings are associated (or correlated) with its Interest Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Interest Expense has no effect on the direction of Operating Income i.e., Regencell Bioscience's Operating Income and Interest Expense go up and down completely randomly.

Correlation Coefficient

0.21
Relationship DirectionPositive 
Relationship StrengthVery Weak

Operating Income

Operating Income is the amount of profit realized from Regencell Bioscience operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Regencell Bioscience Holdings is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.
Most indicators from Regencell Bioscience's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Regencell Bioscience current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
At present, Regencell Bioscience's Enterprise Value Over EBITDA is projected to decrease significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 8.47, whereas Selling General Administrative is forecasted to decline to about 3.8 M.
 2021 2022 2023 2024 (projected)
Total Operating Expenses7.6M6.3M5.6M5.4M
Cost Of Revenue604.4K769.7K885.1K840.9K

Regencell Bioscience fundamental ratios Correlations

0.950.960.99-0.510.98-0.380.920.86-0.640.941.00.790.94-0.410.990.910.950.60.180.950.990.91-0.10.960.99
0.950.840.98-0.760.88-0.131.00.76-0.520.820.950.930.82-0.270.940.990.990.490.051.00.920.730.10.980.93
0.960.840.91-0.30.99-0.590.810.82-0.740.950.960.60.95-0.550.970.780.840.610.160.850.950.96-0.310.860.98
0.990.980.91-0.630.94-0.240.960.86-0.540.90.990.870.9-0.310.970.960.980.540.190.980.970.840.020.990.97
-0.51-0.76-0.3-0.63-0.36-0.45-0.8-0.320.07-0.31-0.52-0.9-0.31-0.13-0.49-0.82-0.74-0.080.19-0.75-0.47-0.13-0.5-0.68-0.47
0.980.880.990.94-0.36-0.550.850.82-0.730.940.980.650.94-0.530.990.820.870.640.160.890.960.95-0.270.890.99
-0.38-0.13-0.59-0.24-0.45-0.55-0.08-0.230.65-0.48-0.380.24-0.470.74-0.44-0.04-0.12-0.39-0.07-0.14-0.36-0.620.86-0.14-0.46
0.921.00.810.96-0.80.85-0.080.73-0.490.780.930.940.78-0.240.911.00.990.470.021.00.890.690.130.970.9
0.860.760.820.86-0.320.82-0.230.73-0.440.890.850.690.89-0.160.820.720.790.520.480.780.90.870.070.850.82
-0.64-0.52-0.74-0.540.07-0.730.65-0.49-0.44-0.61-0.65-0.22-0.610.76-0.69-0.45-0.47-0.620.28-0.52-0.58-0.70.45-0.47-0.7
0.940.820.950.9-0.310.94-0.480.780.89-0.610.930.631.0-0.490.930.780.830.510.280.840.980.92-0.20.850.93
1.00.950.960.99-0.520.98-0.380.930.85-0.650.930.790.93-0.411.00.910.950.610.170.960.980.91-0.10.960.99
0.790.930.60.87-0.90.650.240.940.69-0.220.630.790.630.040.750.950.930.310.10.920.770.50.410.910.73
0.940.820.950.9-0.310.94-0.470.780.89-0.611.00.930.63-0.490.930.770.820.510.280.840.980.92-0.190.850.93
-0.41-0.27-0.55-0.31-0.13-0.530.74-0.24-0.160.76-0.49-0.410.04-0.49-0.47-0.21-0.23-0.320.12-0.27-0.41-0.480.8-0.22-0.48
0.990.940.970.97-0.490.99-0.440.910.82-0.690.931.00.750.93-0.470.890.930.610.140.940.970.91-0.170.941.0
0.910.990.780.96-0.820.82-0.041.00.72-0.450.780.910.950.77-0.210.890.990.430.030.990.880.660.170.960.88
0.950.990.840.98-0.740.87-0.120.990.79-0.470.830.950.930.82-0.230.930.990.440.150.990.920.740.10.980.92
0.60.490.610.54-0.080.64-0.390.470.52-0.620.510.610.310.51-0.320.610.430.44-0.090.490.540.69-0.090.540.62
0.180.050.160.190.190.16-0.070.020.480.280.280.170.10.280.120.140.030.15-0.090.080.260.29-0.140.220.14
0.951.00.850.98-0.750.89-0.141.00.78-0.520.840.960.920.84-0.270.940.990.990.490.080.930.750.090.980.93
0.990.920.950.97-0.470.96-0.360.890.9-0.580.980.980.770.98-0.410.970.880.920.540.260.930.91-0.10.940.97
0.910.730.960.84-0.130.95-0.620.690.87-0.70.920.910.50.92-0.480.910.660.740.690.290.750.91-0.290.790.92
-0.10.1-0.310.02-0.5-0.270.860.130.070.45-0.2-0.10.41-0.190.8-0.170.170.1-0.09-0.140.09-0.1-0.290.1-0.19
0.960.980.860.99-0.680.89-0.140.970.85-0.470.850.960.910.85-0.220.940.960.980.540.220.980.940.790.10.93
0.990.930.980.97-0.470.99-0.460.90.82-0.70.930.990.730.93-0.481.00.880.920.620.140.930.970.92-0.190.93
Click cells to compare fundamentals

Regencell Bioscience Account Relationship Matchups

Regencell Bioscience fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets514.0K340.1K18.0M12.6M11.4M10.8M
Short Long Term Debt Total3.1M3.7M771.3K463.7K417.3K396.4K
Total Current Liabilities3.2M4.3M577.8K606.9K546.2K518.9K
Total Stockholder Equity(2.7M)(4.0M)17.1M12.0M10.8M11.4M
Net Debt2.7M3.6M(5.6M)(1.1M)(991.0K)(941.5K)
Retained Earnings(2.7M)(4.0M)(11.4M)(17.3M)(15.6M)(14.8M)
Cash387.0K59.4K6.4M1.6M1.4M1.3M
Non Current Assets Total127.0K273.3K1.6M1.0M900.4K855.4K
Cash And Short Term Investments387.0K59.4K16.4M11.6M10.4M9.9M
Liabilities And Stockholders Equity514.0K340.1K18.0M12.6M11.4M10.8M
Non Current Liabilities Total3.1M3.7M360.3K25.4K29.2K27.8K
Total Liab3.2M4.3M938.0K632.3K569.1K540.6K
Total Current Assets387.0K66.8K16.4M11.6M10.5M9.9M
Short Term Debt3.1M3.7M411.0K438.3K394.4K374.7K
Net Invested Capital419.0K(315.7K)17.1M12.0M13.8M14.5M
Net Working Capital(2.8M)(4.3M)15.9M11.0M12.7M13.3M
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Regencell Bioscience in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Regencell Bioscience's short interest history, or implied volatility extrapolated from Regencell Bioscience options trading.

Currently Active Assets on Macroaxis

When determining whether Regencell Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regencell Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regencell Bioscience Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regencell Bioscience Holdings Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
Note that the Regencell Bioscience information on this page should be used as a complementary analysis to other Regencell Bioscience's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Complementary Tools for Regencell Stock analysis

When running Regencell Bioscience's price analysis, check to measure Regencell Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regencell Bioscience is operating at the current time. Most of Regencell Bioscience's value examination focuses on studying past and present price action to predict the probability of Regencell Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regencell Bioscience's price. Additionally, you may evaluate how the addition of Regencell Bioscience to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Money Managers
Screen money managers from public funds and ETFs managed around the world
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Is Regencell Bioscience's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.45)
Return On Assets
(0.26)
Return On Equity
(0.42)
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.